FGAM
PACB icon

Financial Gravity Asset Management’s Pacific Biosciences PACB Stock Holding History

Financial Gravity Asset Management’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-47
Closed -$176 – 2127
2024
Q1 		$176 Buy
47
+37
+370% +$217 ﹤0.01% 1631
2023
Q4 		$78 Buy
10
+5
+100% +$41 ﹤0.01% 1285
2023
Q3 		$32 Sell
5
-8
-62% -$91 ﹤0.01% 1083
2023
Q2 		$289 Buy
13
+1
+8% +$12 ﹤0.01% 1075
2023
Q1 		$8 Buy
12
+4
+50% +$40 ﹤0.01% 883
2022
Q4 		$146 Sell
8
-4
-33% -$34 ﹤0.01% 1047
2022
Q3 		$4 Buy
12
+4
+50% +$23 ﹤0.01% 795
2022
Q2 		$3 Sell
8
-10
-56% -$61 ﹤0.01% 715
2022
Q1 		$6 Sell
18
-22
-55% -$253 ﹤0.01% 795
2021
Q4 		$14 Buy
40
+39
+3,900% +$941 ﹤0.01% 840
2021
Q3 		$26K Hold
1
– – 0.01% 742
2021
Q2 		$35K Sell
1
-1
-50% -$29 0.01% 674
2021
Q1 		$70 Buy
+2
New +$70 ﹤0.01% 527

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
EDRH
Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Financial Gravity Asset Management's PACB Position: Q2 2024 in Review

Financial Gravity Asset Management sold out of Pacific Biosciences (PACB) in Q2 2024, closing a stake of 47 shares — an estimated $176 sold.

Financial Gravity Asset Management first reported a position in PACB in Q1 2021 and held it in 13 quarters. The position peaked at $35K in Q2 2021. 228 funds tracked by Wall St. Rank hold PACB as of Q2 2024.

  • Financial Gravity Asset Management reported no remaining Pacific Biosciences position as of Q2 2024 after selling out during the quarter.
  • Financial Gravity Asset Management sold 47 Pacific Biosciences shares in Q2 2024, an estimated $176.
  • Financial Gravity Asset Management first reported a position in Pacific Biosciences in Q1 2021 and held it in 13 quarters.
  • Financial Gravity Asset Management's Pacific Biosciences position peaked at $35K in Q2 2021.
  • 228 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2024.

Based on Financial Gravity Asset Management's 13F filing for Q2 2024, filed 6 Aug 2024.